morpholinoanthracycline mx2 has been researched along with Astrocytoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, J; Basser, RL; Byrne, M; Cher, L; Clarke, K; Dalley, D; Findlay, M; Fox, RM; Geldard, H; Green, MD; Hill, JS; Kaye, AH; Maher, D; Mitchell, P; Pell, M; Underhill, C | 1 |
| Arita, N; Kayama, T; Kubo, N; Kuratsu, JI; Mori, T; Sawamura, Y; Ushio, Y | 1 |
2 trial(s) available for morpholinoanthracycline mx2 and Astrocytoma
| Article | Year |
|---|---|
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Carubicin; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis | 1999 |
Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Topics: Adult; Antibiotics, Antineoplastic; Astrocytoma; Brain Neoplasms; Cardiomyopathies; Carubicin; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Glioblastoma; Humans; Leukopenia; Male; Middle Aged; Nausea; Oligodendroglioma; Treatment Outcome; Vomiting | 2000 |